The S&P 500 has traded in a narrow range this summer, hovering roughly 3% below its June high. But beneath the surface, a significant sector rotation is reshaping the market. Institutional capital is flowing out of technology stocks and into healthcare and financials—both sectors have posted double-digit gains since June. This shift reflects a broader repositioning toward earnings-driven names rather than a retreat from equities. Two stocks that stand out in this environment are Eli Lilly (LLY) and Enova International (ENVA).
Eli Lilly: Healthcare Momentum Meets Technical Breakout
Eli Lilly has become a prime beneficiary of the rotation into healthcare. After spending seven months pinned below the $1,200 resistance level, the stock finally broke out this month. It is now completing a throwback pattern, consolidating gains within a tight, downward-sloping flag that sits just above prior resistance. The shares trade comfortably above their short- and long-term moving averages, which are stacked in a bullish alignment (21-day above 50-day above 200-day). Meanwhile, the LLY/SPY relative strength ratio is trending toward record highs, signaling continued outperformance.
Fundamentally, Eli Lilly’s forward P/E of roughly 34x is elevated, but it is supported by strong GLP-1-driven momentum. The company is projected to grow revenue by 31% and earnings per share by 43% this year. Wall Street analysts maintain a Strong Buy consensus, with price targets as high as $1,600—implying potential upside of more than 33% from current levels. A modest 0.57% dividend yield adds to the stock’s appeal for long-term holders. For context on broader market trends, see our coverage of recent Dow gains and chip stock weakness.
Enova International: High Growth at a Reasonable Price
Within financials, Enova International offers a compelling mix of high growth and valuation discipline. The tech-enabled lender, which operates brands like CashNetUSA, NetCredit, and OnDeck, is consolidating near 52-week highs after a steep summer rally. The stock is forming a tight pennant pattern, with robust volume accumulation on up days and multi-month highs in its relative strength ratio versus the broader market. Shares trade well above key moving averages, indicating that bulls remain in control across multiple timeframes.
Enova’s fundamentals are equally strong. The company grew its bottom line by 33% in the latest reported quarter and trades at just over 13x forward earnings. Projected revenue growth of 18% and 22% over the next two fiscal years, paired with EPS growth expectations of 33% and 20%, reflect resilient credit conditions. Wall Street analysts rate Enova a Strong Buy, with price targets as high as $300—suggesting roughly 23% upside. Unlike Eli Lilly, Enova does not pay a dividend. For more on sector dynamics, see our analysis of chip stock selloffs and Fed expectations.
What the Rotation Means for Investors
The ongoing rotation underscores a shift in market leadership. As technology stocks face headwinds from valuation concerns and regulatory scrutiny, capital is moving into sectors with stronger earnings visibility and more attractive valuations. Healthcare and financials are benefiting from this trend, and stocks like Eli Lilly and Enova International are well-positioned to capture further gains. Investors should monitor technical levels and earnings reports for confirmation of these trends. For additional context on market movements, check our piece on European stocks and oil price retreats.
This article is for informational purposes only and does not constitute financial advice.
